Weight-loss drugs could reduce COVID-related deaths: Study

Published On Sep 3, 2024, 9:31 AM

A recent study suggests that weight-loss drugs, specifically semaglutide (the active ingredient in Novo Nordisk's drugs Wegovy and Ozempic), could significantly reduce the risk of death from COVID-19. The study observed a group of overweight or obese patients with pre-existing cardiovascular conditions and found a 34% decrease in mortality risk from COVID-19 among those using semaglutide. The global market for obesity drugs is expected to grow dramatically, potentially reaching between $105 billion and $144 billion by 2030, as they are also seen as beneficial for treating various other illnesses.

Read full article

Stock Forecasts

NVOView NVO chart on TradingView

Positive

Given the increasing recognition of semaglutide and similar drugs in reducing health risks associated with obesity and diseases like COVID-19, investment in companies producing these medications appears promising. Novo Nordisk, as a leader in this market, is well-positioned for future growth as the demand for obesity treatment rises and the market expands.

Related News

Weight-loss drug competition heats up with growing pill market

Sep 17, 2024, 5:32 PM

GLP-1 pills are the next frontier for the weight-loss market.

LLY
NVO
PFE

Weight-loss drugs could reduce COVID-related deaths: Study

Sep 3, 2024, 9:31 AM

A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.

NVO